Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.47 |
| ▸ | WDR5 | P61964 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.36 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23988434 | 0.90 | WDR5 (0.57) | SARM1WDR5KMT2ANPC1RAB9A | |
| SCHEMBL23988449 | 0.89 | SARM1 (0.61) | SARM1WDR5KMT2ANPC1RAB9A | |
| SCHEMBL23988502 | 0.83 | SARM1 (0.36) | SARM1WDR5KMT2AHSD17B10ALDH1A1 | |
| SCHEMBL23988430 | 0.82 | CYP2C9 (0.48) | SARM1WDR5KMT2ANPC1RAB9A | |
| SCHEMBL24571890 | 0.77 | KMT2A (0.49) | SARM1WDR5KMT2ANPC1RAB9A | |
| SCHEMBL23988591 | 0.77 | BRS3 (0.51) | SARM1WDR5KMT2ANPC1RAB9A | |
| SCHEMBL23988366 | 0.76 | CYP2C9 (0.47) | SARM1WDR5KMT2ANPC1RAB9A | |
| SCHEMBL23988497 | 0.75 | KMT2A (0.41) | SARM1WDR5KMT2AHSD17B10ALDH1A1 | |
| SCHEMBL23988508 | 0.73 | KMT2A (0.47) | SARM1WDR5KMT2ANPC1RAB9A | |
| SCHEMBL23988437 | 0.72 | NPC1 (0.44) | SARM1WDR5KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338650-A1 | CXCL10 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338650-A1 | CXCL10 Inhibitors | CXCL10, CCL5, CCL11 | SARM1 3076/4885WDR5 3395/4885KMT2A 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.